1.
Lindholm JF, Juul S, Jørgensen JO, Astrup J, Bjerre P, et al. Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 2001;86:117–23.CrossrefGoogle Scholar
2.
Magiakou MA, Chrousos GP. Cushing’s syndrome in children and adolescents: current diagnostic and therapeutic strategies. J Endocrinol Invest 2002;25:181–94.Google Scholar
3.
Savage MO, Besser GM. Cushing’s disease in childhood. Trends Endocrinol Metab 1996;7:213–6.CrossrefGoogle Scholar
4.
Magiakou MA, Mastorakos G, Oldfield EH, Gomez MT, Doppman JL, et al. Cushing’s syndrome in children and adolescents. Presentation, diagnosis and therapy. N Engl J Med 1994;331:629–36.Google Scholar
5.
Newell-Price JF, Trainer PF, Besser MF, Grossman AB. The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 1998;19:647–72.CrossrefGoogle Scholar
6.
Nieman LK. Diagnostic tests for Cushing’s syndrome. Ann NY Acad Sci 2002;970:112–8.Google Scholar
7.
Boscaro MF, Barzon LF, Fallo FF, Sonino N. Cushing’s syndrome. Lancet 2001;357:783–91.Google Scholar
8.
Stratakis CA. Adrenocortical tumors, primary pigmented adrenocortical disease (PPNAD)/Carney complex, and other bilateral hyperplasias: the NIH studies. Horm Metab Res 2007;39:467–73.PubMedCrossrefWeb of ScienceGoogle Scholar
9.
Gunther DF, Bourdeau I, Matyakhina L, Cassarino D, Kleiner DE, et al. Cyclical Cushing syndrome presenting in infancy: an early form of primary pigmented nodular adrenocortical disease, or a new entity? J Clin Endocrinol Metab 2004;89:3173–82.PubMedCrossrefGoogle Scholar
10.
Savage MO, Lienhardt AF, Lebrethon MC, Johnston LB, Huebner A, et al. Cushing’s disease in childhood: presentation, investigation, treatment and long-term outcome. Horm Res 2001;55:24–30.CrossrefGoogle Scholar
11.
Normann T, Hanven J, Mjolnerod O. Cushing syndrome in an infant associated with neuroblastoma in two ectopic adrenal glands. J Pediatr Surg 1971;6:169–75.CrossrefGoogle Scholar
12.
Arioglu E, Doppman J, Gomes M, Kleiner D, Mauro D, et al. Cushing’s syndrome caused by corticotropin secretion by pulmonary tumorlets. N Engl J Med 1998;339:883–6.Google Scholar
13.
Arnaldi GF, Angeli AF, Atkinson AB, Bertagna X, Cavagnini F, et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2003;88: 5593–602.CrossrefGoogle Scholar
14.
Magiakou MA, Mastorakos G, Chrousos GP. Final stature in patients with endogenous Cushing’s syndrome. J Clin Endocrinol Metab 1994;79:1082–5.CrossrefGoogle Scholar
15.
Lebrethon MC, Grossman AB, Afshar FF, Plowman PN, Besser GM, et al. Linear growth and final height after treatment for Cushing’s disease in childhood. J Clin Endocrinol Metab 2000;85:3262–5.CrossrefGoogle Scholar
16.
Kudielka BM, Buske-Kirschbaum A, Hellhammer DH, Kirschbaum C. HPA axis responses to laboratory psychosocial stress in healthy elderly adults, younger adults, and children: impact of age and gender. Psychoneuroendocrinology 2004;29:83–98.PubMedCrossrefGoogle Scholar
17.
Kuperman H, Damiani D, Chrousos GP, Dichtchekenian V, Manna TD, et al. Evaluation of the hypothalamic-pituitary-adrenal axis in children with leukemia before and after 6 weeks of high-dose glucocorticoid therapy. J Clin Endocrinol Metab 2001;86:2993–6.PubMedCrossrefGoogle Scholar
18.
Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer 2006;6:193–203.PubMedCrossrefGoogle Scholar
19.
Barredo J, Ritchey AK. Controversies in the management of central nervous system leukemia. Pediatr Hematol Oncol 2010;27:329–32.Web of SciencePubMedCrossrefGoogle Scholar
20.
Talıaferro I. Cushing’s syndrome associated with acute leukemia. South Med J 1961;54:686–9.CrossrefGoogle Scholar
21.
Pflüger KH, Gramse M, Gropp C, Havemann K. Ectopic ACTH production with autoantibody formation in a patient with acute myeloblastic leukemia. N Engl J Med 1981;305:1632–6.Google Scholar
22.
Tilley E, Ryalls MR, Williams MP. CT demonstration of pituitary stalk relapse in childhood acute lymphoblastic leukaemia. Clin Radiol 1989;40:634–5.CrossrefPubMedGoogle Scholar
23.
Muller CI, Engelhardt M, Laubenberger J, Kunzmann R, Engelhardt R, et al. Myelodysplastic syndrome in transformation to acute myeloid leukemia presenting with diabetes insipidus: due to pituitary infiltration association with abnormalities of chromosomes 3 and 7. Eur J Haematol 2002;69:115–9.Google Scholar
24.
Rye AD, Stitson RN, Dyer MJ. Pituitary infiltration in B cell chronic lymphocytic leukaemia. Br J Haematol 2001;115:718.CrossrefGoogle Scholar
25.
Shek TW, Au WY. Conjunctival relapse of acute lymphoblastic leukemia heralding pituitary and CNS disease. J Clin Oncol 2005;23:4225–30.PubMedGoogle Scholar
26.
Nemoto K, Ohnishi Y, Tsukada T. Chronic lymphocytic leukemia showing pituitary tumor with massive leukemic cell infiltration, and special reference to clinicopathological findings of CLL. Acta Pathol Japon 1978;28:797–805.Google Scholar
27.
Metcalf D. The unsolved enigmas of leukemia inhibitory factor. Stem Cells 2003;21:5–14.PubMedCrossrefGoogle Scholar
28.
Tomida M, Yamamoto-Yamaguchi Y, Hozumi M. Purification of a factor inducing differentiation of mouse myeloid leukemic Ml cells from conditioned medium of mouse fibroblast L929 cells. J Biol Chem 1984;259:10978–82.Google Scholar
29.
Metcalf D. Leukemia inhibitory factor-a puzzling polyfunctional regulator. Growth Factors 1992;7:169–73.PubMedCrossrefGoogle Scholar
30.
Sun H, Shi WK. Expression of LIF gene during early development of mouse embryo. J Exp Biol 1998;31:105–9.Google Scholar
31.
Fukada K, Korsching S, Towle MF. Tissue-specific and ontogenetic regulation of LIF protein levels determined by quantitative enzyme immunoassay. Growth Factors 1997;14:279–95.PubMedCrossrefGoogle Scholar
32.
Chesnokova V, Melmed S. Leukemia inhibitory factor mediates the hypothalamic pituitary adrenal axis response to inflammation. Endocrinology 2000;141:4032–40.Google Scholar
33.
Ancey C, Corbi P, Froger J, Delwail A, Wijdenes J, et al. Secretion of IL-6, IL-11 and LIF by human cardiomyocytes in primary culture. Cytokine 2002;18:199–205.Google Scholar
34.
Morel DS, Taupin JL, Potier M, Deminière C, Potaux L, et al. Renal synthesis of leukaemia inhibitory factor (LIF), under normal and inflammatory conditions. Cytokine 2000;12: 265–71.CrossrefPubMedGoogle Scholar
35.
Tofaris GK, Patterson PH, Jessen KR, Mirsky R. Denervated Schwann cells attract macrophages by secretion of leukemia inhibitory factor (LIF) and monocyte chemoattractant protein-1 in a process regulated by interleukin-6 and LIF. J Neurosci 2002;22:6696–703.Google Scholar
36.
Bonifati C, Mussi A, D’Auria L, Carducci M, Trento E, et al. Spontaneous release of leukemia inhibitory factor and oncostatin-M is increased in supernatants of short-term organ cultures from lesional psoriatic skin. Arch Dermatol Res 1998;290:9–13.Google Scholar
37.
Chesnokova V, Kariagina A, Melmed S. Opposing effects of pituitary leukemia inhibitory factor and SOCS-3 on the ACTH axis response to inflammation. Am J Physiol Endocrinol Met 2002;282:1110–8.Google Scholar
38.
Tomida M, Yoshida U, Mogi C, Maruyama M, Goda H, et al. Leukaemia inhibitory factor and interleukin 6 inhibit secretion of prolactin and growth hormone by rat pituitary MtT/SM cells. Cytokine 2001;14:202–7.PubMedGoogle Scholar
39.
Kendall SK, Gordon DF, Birkmeier TS, Petrey D, Sarapura VD, et al. Enhancer-mediated high level expression of mouse pituitary glycoprotein hormone a-subunit transgene in thyrotropes, gonadotropes, developing pituitary gland. Mol Endocrinol 1994;8:1420–33.PubMedCrossrefGoogle Scholar
40.
Burrows HL, Birkmeier TS, Seasholtz AF, Camper SA. Targeted ablation of cells in the pituitary primordia of transgenic mice. Mol Endocrinol 1996;10:1467–77.PubMedCrossrefGoogle Scholar
41.
Bousquet C, Ray DW, Melmed SA. Common proopiomelanocortin-binding element mediates leukemia inhibitory factor and corticotropin-releasing hormone transcriptional synergy. J Biol Chem 1997;272:10551–7.Google Scholar
42.
Ray DW, Ren SG, Melmed S. Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line. Role of STAT pathway. J Clin Invest 1996;97:1852–9.CrossrefGoogle Scholar
43.
Xiao R, Chen T, Zhou M, Yang JH, Jiang NK, et al. Abnormal expression of hematopoietic regulatory factors in newly diagnosed patients with acute myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010;18:1124–7.Google Scholar
44.
Wetzler M, Kurzrock R, Lowe DG, Kantarjian H, Gutterman JU, et al. Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression. Blood 1991;78:2400–6.PubMedGoogle Scholar
Comments (0)